Key result
STING activation drives CD8+ T-cell cardiotropism, inflammation, and fibroblast activation in doxorubicin cardiotoxicity.
Why the study?
Doxorubicin cardiotoxicity is characterized by DNA damage, cardiac cell death, fibrosis, and a cytotoxic CD8+ T-cell response with elevated interferon-inducible chemokines.
STING acts as a cell-specific driver of CD8+ T-cell cardiac inflammation and fibroblast activation in doxorubicin-induced cardiotoxicity, highlighting a potential therapeutic target.
May support cell-specific STING modulation to limit doxorubicin cardiotoxicity; leaves open clinical translation from animal models.
AIMS: Doxorubicin (DR), a widely prescribed chemotherapy, has an unfortunate side effect of cardiotoxicity resulting from DNA damage and cardiac cell death. Cardiac atrophy, fibrosis and a cytotoxic CD8+ T-cell response, alongside increased cardiac and circulating interferon-inducible chemokines are hallmarks for DR cardiotoxicity. METHODS AND RESULTS: We discovered that the activation of the Stimulator of Interferon Genes (STING) in several distinct cardiac cell compartments is central to CD8+ T-cell cardiotropism and DR cardiotoxicity. DR activates STING in cardiac fibroblasts (CFB), endothelial cells (EC) and myeloid cells in vivo and in vitro. Myeloid STING is required for CD8+ T-cell activation and cardiotropism, whereas EC STING mediates CD8+ T-cell cardiotropism towards CXCL9/10 and transendothelial migration. In contrast, cardiac fibroblast STING is dispensable for the cardiac CD8+ T-cell immune response but drives fibroblast transformation. We report CXCR3+ T-cells and CXCL9/CXCL10 are more abundant in the hearts of DR cardiotoxicity patients. CONCLUSIONS: Our work positions STING as a cell-specific driver of CD8+ T-cell cardiac inflammation and fibroblast activation in DR cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Bayer et al. (2026) studied Doxorubicin cardiomyopathy. Doxorubicin was evaluated on CD8+ T-cell cardiotropism and DR cardiotoxicity. STING activation in distinct cardiac cell compartments drives CD8+ T-cell cardiotropism, inflammation, and fibroblast activation in doxorubicin cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: